Moreover, while ROS can reportedly also upregulate MUL1 expression and induce AKT degradation in different types of cancer [16, 31, 32], in our study, we did not find that pharmacological VC treatment could promote AKT degradation. This evidence concerns the gene AKT1 and cancer.